Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment
Autor: | Michelle Sittig, Eugene V. Millar, Traci L. Testerman, Jessica L. Metcalf, Carol Nieroda, Faith C. Blum, D. Scott Merrell, Armando Sardi, Mary Caitlin King, Thomas J. McAvoy |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty medicine.drug_class Antibiotics 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Pseudomyxoma peritonei Pre and post business.industry Intraperitoneal chemotherapy Cytoreduction Surgical Procedures Hyperthermia Induced General Medicine Pseudomyxoma Peritonei medicine.disease Combined Modality Therapy Anti-Bacterial Agents Peritoneal carcinomatosis 030104 developmental biology 030220 oncology & carcinogenesis Female Surgery Hyperthermic intraperitoneal chemotherapy business Cytoreductive surgery |
Zdroj: | European Journal of Surgical Oncology. 45:1723-1726 |
ISSN: | 0748-7983 |
DOI: | 10.1016/j.ejso.2019.01.223 |
Popis: | Pseudomyxoma peritonei (PMP) is a subtype of peritoneal carcinomatosis that is traditionally treated by cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). A growing body of evidence suggests that microbes are associated with various tumor types and have been found in organs and cavities that were once considered sterile. Prior and ongoing research from our consortium of PMP researchers strongly suggests that bacteria are associated with PMP tumors. While the significance of this association is unclear, in our opinion, further research is warranted to understand whether these bacteria contribute to the development, maintenance and/or progression of PMP. Elucidation of a possible causal role for bacteria in PMP could suggest a benefit for supplementation of antibiotics to current treatment protocols. |
Databáze: | OpenAIRE |
Externí odkaz: |